Overview

Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease

Status:
Completed

Trial end date:
2020-11-30

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the effect of VPRIV therapy (60 units per kilogram [U/kg] every other week [EOW]) in treatment-naive participants with type 1 Gaucher disease on change from baseline in lumbar spine (LS) bone mineral density (BMD) Z-score as measured by dual energy x-ray absorptiometry (DXA) after 24 months of treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Shire

Treatments:

Hydroxycholecalciferols
Vitamin D